Galera to present one-year reductions in cisplatin-related chronic kidney disease data from roman trial at 2023 american society of clinical oncology (asco) annual meeting

Malvern, pa., april 26, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a prespecified analysis from the phase 3 roman trial detailing one-year reductions in cisplatin-related chronic kidney disease in patients with head and neck cancer treated with avasopasem will be presented at the 2023 american society of clinical oncology (asco) annual meeting, taking place june 2-6, 2023, in chicago, il.
GRTX Ratings Summary
GRTX Quant Ranking